Changshan Pharmaceutical (300255.SZ): There is still uncertainty about whether abenatide can finally be approved for marketing and when

Zhitong Finance App News, Changshan Pharmaceutical (300255.SZ) issued an announcement of abnormal stock trading fluctuations, stating that the company's abenatide injections have not yet been marketed. The company's marketing license application for epenatide injections to treat type 2 diabetes is currently in the review stage. The company is providing additional information in accordance with the notice requirements of the Drug Evaluation Center of the State Drug Administration, and has not yet completed the review. There is still uncertainty about whether and when abenatide will eventually be approved for marketing. There are many types of drugs to treat type 2 diabetes. GLP‑1RA is one of them. Even if avenatide is marketed in the future, it faces a high risk of market competition, and there is great uncertainty about the profit situation.